Douglas Lane & Associates LLC Raises Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Douglas Lane & Associates LLC grew its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 460,178 shares of the medical equipment provider’s stock after purchasing an additional 28,818 shares during the quarter. Douglas Lane & Associates LLC owned approximately 0.23% of Zimmer Biomet worth $41,379,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in ZBH. Dodge & Cox grew its holdings in shares of Zimmer Biomet by 5.1% during the third quarter. Dodge & Cox now owns 23,216,173 shares of the medical equipment provider’s stock worth $2,286,793,000 after buying an additional 1,118,710 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Zimmer Biomet by 276.6% during the second quarter. AQR Capital Management LLC now owns 1,300,593 shares of the medical equipment provider’s stock worth $118,627,000 after buying an additional 955,284 shares during the last quarter. Capital International Investors grew its holdings in shares of Zimmer Biomet by 11.5% during the third quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock worth $743,749,000 after buying an additional 778,467 shares during the last quarter. Schonfeld Strategic Advisors LLC grew its holdings in shares of Zimmer Biomet by 3,633.7% during the third quarter. Schonfeld Strategic Advisors LLC now owns 464,250 shares of the medical equipment provider’s stock worth $45,729,000 after buying an additional 451,816 shares during the last quarter. Finally, Victory Capital Management Inc. grew its holdings in shares of Zimmer Biomet by 24.9% during the third quarter. Victory Capital Management Inc. now owns 1,924,763 shares of the medical equipment provider’s stock worth $198,617,000 after buying an additional 383,570 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $92.99 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55. The company has a market cap of $18.00 billion, a P/E ratio of 26.27, a PEG ratio of 1.90 and a beta of 0.61. Zimmer Biomet Holdings, Inc. has a 52 week low of $84.59 and a 52 week high of $108.29. The company has a 50-day moving average price of $92.80 and a 200 day moving average price of $93.49.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.38 by $0.04. The firm had revenue of $2.24 billion during the quarter, compared to the consensus estimate of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The firm’s revenue was up 10.9% compared to the same quarter last year. During the same quarter last year, the firm earned $2.31 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be given a $0.24 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 27.12%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Barclays lowered their price target on Zimmer Biomet from $104.00 to $100.00 and set an “underweight” rating on the stock in a report on Thursday, February 12th. Evercore raised Zimmer Biomet from an “in-line” rating to an “outperform” rating and raised their price target for the stock from $94.00 to $120.00 in a report on Monday, January 5th. BTIG Research reissued a “neutral” rating on shares of Zimmer Biomet in a report on Monday, March 23rd. Wells Fargo & Company raised their price target on Zimmer Biomet from $93.00 to $98.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 11th. Finally, The Goldman Sachs Group lowered Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price target on the stock. in a report on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $106.20.

Insider Buying and Selling

In related news, SVP Lori Winkler sold 2,650 shares of the firm’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total value of $250,849.00. Following the completion of the sale, the senior vice president owned 10,224 shares in the company, valued at $967,803.84. This trade represents a 20.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.39% of the stock is currently owned by insiders.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.